Suspect company in foot-and-mouth scare up and running again

NewsGuard 100/100 Score

The drug company at the centre of the foot-and-mouth outbreak in Britain has been allowed to re-start production.

The outbreak which resulted in herds of cattle being culled also triggered a nationwide ban on the movement of livestock.

Merial Animal Health shares the Pirbright laboratory complex in Surrey with the Institute for Animal Health and an interim report found there was a "strong probability" the complex was the source of the outbreak.

Merial halted vaccine production on the 4th of August after an outbreak of foot-and-mouth disease was confirmed on a farm in Normandy near Guildford; the strain of the disease was identical to that being used by Merial, but was also being used on a much smaller scale by the Institute for Animal Health.

Merial says it has been given the green light from the Veterinary Medicines Directorate to re-start production using a non-live virus.

The company will not be allowed to resume manufacturing vaccines using live virus until the government has considered the two investigations into the source of the outbreak.

Merial says they are keen to see the results of the investigations into the cause of the foot-and-mouth disease outbreak, and will continue to work with the investigators as required.

The company insists they have found no evidence that the outbreak in Surrey can be traced to any failure in their bio-security procedures or equipment.

Merial have operated at Pirbright for 15 years and say there has never been a breach of bio-security at their operations.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Unraveling the complexities of muscle repair in diabetes: A call for targeted research and therapies